Phase III FIRSTa (MM-020/IFM 07-01) Trial of REVLIMIDA ...

4 issue of the New England Journal of Medicine . Initial findings, including that the trial had met its primary endpoint of progression free survival , were reported during the plenary session at the 55th American Society of Hematology annual meeting in December 2013.

http://ift.tt/1w9Viyz